Clinical Trials Logo

Myositis clinical trials

View clinical trials related to Myositis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05627089 Withdrawn - Clinical trials for Rheumatoid Arthritis

Rheumatoid Arthritis and Myositis Cohort

Start date: July 1, 2023
Phase:
Study type: Observational

The primary objective of this research is to establish a well characterized clinical and longitudinal cohort for individuals with Rheumatoid Arthritis (RA) and Myositis to create a place to maintain blood, urine, stool specimens, excess tissue from procedures, and clinical data, which may be accessed for future research purposes. Specific research objectives of this cohort include: 1. Observe the response that immunosuppressive medications have on the immune cell population and cytokines in individuals with RA or Myositis. 2. Observe the role that the intestinal microbiome has on the immune cell population and cytokines in individuals with RA or Myositis. 3. Observe the connection between intestinal inflammation has on the immune cell population and cytokines in individuals with RA or Myositis.

NCT ID: NCT03710941 Withdrawn - Clinical trials for Sporadic Inclusion Body Myositis

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Start date: February 19, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of REGN2477+REGN1033 in combination on total lean mass, as measured by Dual-energy X-ray absorptiometry (DXA) in patients with sporadic inclusion body myositis (sIBM). The secondary objectives of the study are: - To evaluate the efficacy of REGN2477+REGN1033 on the IBM-Functional Rating Scale (IBM-FRS) - To evaluate the efficacy of REGN2477+REGN1033 on the sIBM Physical Functioning Assessment (sIFA) - To evaluate the safety and tolerability of REGN2477+REGN1033 - To evaluate the effects of REGN2477+REGN1033 on body composition by DXA, including appendicular lean mass and total fat mass - To evaluate the efficacy of REGN2477+REGN1033 on measures of muscle performance and physical function - To evaluate the efficacy of REGN2477+REGN1033 on patient reported outcome measures including the fear of falling, falls and near falls, and health-related quality of life - To evaluate the pharmacokinetic(s) (PK) profile of REGN2477+REGN1033, including functional REGN2477 and functional REGN1033 concentrations in serum over time - To evaluate the immunogenicity of REGN2477+REGN1033